Citizens Jmp Increases argenex (NASDAQ:ARGX) Price Target to $944.00

argenex (NASDAQ:ARGX) had its target price raised by equities research analysts at Citizens Jmp from $925.00 to $944.00 in a report issued on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price suggests a potential upside of 23.09% from the company’s previous close.

ARGX has been the subject of a number of other research reports. Guggenheim cut their price target on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday. Truist Financial increased their target price on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Wedbush reiterated an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Wednesday, January 14th. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, HC Wainwright raised their price objective on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and an average target price of $999.22.

argenex Trading Down 0.6%

Shares of argenex stock opened at $766.92 on Friday. The company has a fifty day simple moving average of $826.36 and a 200-day simple moving average of $811.97. The stock has a market cap of $47.46 billion, a price-to-earnings ratio of 39.29, a PEG ratio of 0.67 and a beta of 0.37. argenex has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, beating the consensus estimate of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 63.59%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. On average, analysts forecast that argenex will post 3.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenex

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital World Investors grew its stake in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares in the last quarter. M&T Bank Corp grew its stake in argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after buying an additional 774,916 shares during the last quarter. Wellington Management Group LLP boosted its stake in argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the period. Morgan Stanley raised its holdings in shares of argenex by 19.2% during the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after buying an additional 83,746 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.